EMILEA HARSHMAN: Open Payments
NPI 1831684216 · LINCOLN, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,007 in 56 payments from 21 companies in 2025. Trend: 2023 $759 · 2024 $1,246 · 2025 $1,007
Food & beverage: $1,007
| Company | Payments | Amount |
|---|---|---|
| PFIZER INC. | 12 | $205 |
| Lilly USA, LLC | 10 | $132 |
| Novo Nordisk Inc | 5 | $88 |
| ABBVIE INC. | 3 | $83 |
| Astellas Pharma US Inc | 2 | $68 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $65 |
| AstraZeneca Pharmaceuticals LP | 2 | $38 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $36 |
| Axsome Therapeutics, Inc. | 2 | $33 |
| Kowa Pharmaceuticals America, Inc. | 2 | $30 |
Products named: NURTEC ODT, VRAYLAR, Veozah, CAPLYTA, MOUNJARO, PREVNAR 20, REXULTI, KISUNLA.
Industry payments across NE — which companies pay providers there.
